Back to News
Market Impact: 0.35
What Ironwood Pharmaceuticals (IRWD) Said on Its Q3 Earnings Call
Source: marketbeat.com
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Ironwood Pharmaceuticals raised its 2026 financial outlook after third-quarter LINZESS sales reached $325 million. The company attributed the drug's performance to improved net pricing and prescription demand; the article provides no size for the outlook increase.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
IRWD0.65
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook